A phase I study of anti-inflammatory therapy with rilonacept in adolescents and adults with type 1 diabetes mellitus-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A phase I study of anti-inflammatory therapy with rilonacept in adolescents and adults with type 1 diabetes mellitus

Published:2018-03-04 Issue:4 Volume:19 Page:788-793
ISSN:1399-543X
Container-title:Pediatric Diabetes
language:en
Short-container-title:Pediatr Diabetes

Author:

White Perrin C¹^ORCID,Adhikari Soumya¹,Grishman Ellen K¹,Sumpter Kathryn M¹

Affiliation:

1. Division of Pediatric Endocrinology; University of Texas Southwestern Medical Center; Dallas Texas

Funder

Regeneron Pharmaceuticals

Publisher

Wiley

Subject

Endocrinology, Diabetes and Metabolism,Pediatrics, Perinatology and Child Health,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/pedi.12634/fullpdf

Reference41 articles.

1. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials;Moran;Lancet,2013

2. B-lymphocyte depletion with rituximab and beta-cell function: two-year results;Pescovitz;Diabetes Care,2014

3. Antithymocyte globulin plus G-CSF combination therapy leads to sustained immunomodulatory and metabolic effects in a subset of responders with established type 1 diabetes;Haller;Diabetes,2016

4. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial;Rigby;Lancet Diabetes Endocrinol,2013

5. Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial;Sherry;Lancet,2011

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research Advances in Fusion Protein-Based Drugs for Diabetes Treatment;Diabetes, Metabolic Syndrome and Obesity;2024-01

2. Exploration of Immune Targets for Type 1 Diabetes and Latent Autoimmune Disease Immunotherapy;ImmunoTargets and Therapy;2023-09

3. Anti‐viral innate immunity: Is it where type 1 diabetes really begins?;Diabetes/Metabolism Research and Reviews;2023-02-17

4. Therapeutic targeting of inflammasome signaling by blocking interleukin-1;Inflammasome Biology;2023

5. Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders;Frontiers in Immunology;2022-07-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3